Insulet Corporation (PODD) Q2 Revenue Surges 32.9% to $649M, Raises Full-Year Guidance

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Insulet Corporation is one of them.

Insulet Corporation (NASDAQ:PODD) is a global leader in tubeless insulin pump technology, offering innovative diabetes management solutions through its Omnipod Insulin Management System. The flagship Omnipod 5 Automated Insulin Delivery System integrates with continuous glucose monitors to deliver automated, needle-free insulin dosing for type 1 and type 2 diabetes patients, controlled via smartphone or Omnipod controller.

In Q2 2025, Insulet Corporation (NASDAQ:PODD) reported $649.1 million in revenue, up 32.9% year-over-year, driven by strong customer adoption in the U.S. and international markets. The Omnipod product line generated $639 million, with gross margins of 69.7% and operating income of $121.1 million. Net income reached $22.5 million, or $0.32 per share, further cementing PODD’s reputation among the best healthcare stocks. Following this performance, the corporation raised its full-year revenue growth guidance to 24–27% and adjusted operating margin guidance to 17–17.5%.

PODD also strengthened its brand identity through a partnership with Pantone®, launching Omnipod Mango, a vibrant new color celebrating the diabetes community. Insulet Corporation (NASDAQ:PODD) continues expanding Omnipod 5 compatibility with multiple continuous glucose monitors and advancing international adoption, including in Europe, where Omnipod 5 is now the first automated insulin delivery system prescribed for new users.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.